

Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, NW
Washington, DC 20004
Tel: 202.739.3000
Fax: 202.739.3001
www.morganlewis.com



Morgan Lewis
C O U N S E L O R S A T L A W

July 27, 2005

VIA AIR MAIL

CONFIDENTIAL COMMUNICATION

Kevin Stansfield
AstraZeneca
R&D Headquarters
Global Intellectual Property
S-151 85, Södertälje
SWEDEN

Re: U.S. Patent Application No.: 10/813,426
Inventors: Lilian ALCARAZ et al.
Your Reference: A2293-1P US
Our Reference: 056291-5103-01

Dear Kevin:

Enclosed is a copy of the Official Filing Receipt issued by the U.S. Patent and Trademark Office for the above referenced patent application. We have checked the information printed on the Receipt and note that the second and fourth inventors' names and addresses were omitted.

We have filed a Request for Correction and have enclosed a copy of our request. We will forward the corrected Filing Receipt as soon as it is received.

With best regards.

Sincerely,

Donald J. Bird

DJB/lmp
Enclosures



IFW

PATENT
ATTORNEY DOCKET NO. 056291-5103-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In-re Application of: Lilian ALCARAZ et al.

Application No.: 10/813,426

Filed: March 31, 2004

For: ADAMANTANE DERIVATIVES

Commissioner for Patents

MAIL STOP PATENT APPLICATION

Alexandria, Virginia 22314

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

There is an error with respect to the following data which is:

- ☐ incorrectly entered
☒ omitted

Error In

Correct Data

☒ Second Inventor's Name and Address


Moya CAFFREY -
Loughborough, United Kingdom

☒ Fourth Inventor's Name and Address

Timothy LUKER -
Loughborough, United Kingdom

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Donald J. Bird
Reg. No. 25,323

Dated: July 27, 2005
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
(202)739-3000



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/813,426	03/31/2004	1626	1526	056291-5103-01		12	2

09629

MORGAN LEWIS & BOCKIUS LLP
 1111 PENNSYLVANIA AVENUE NW
 WASHINGTON, DC 20004

CONFIRMATION NO. 3791

UPDATED FILING RECEIPT

OC000000014427525

OC000000014427525

Date Mailed: 11/22/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Lilian Alcaraz, Loughborough, UNITED KINGDOM;
 Mark Furber, Loughborough, UNITED KINGDOM;
 Michael Mortimore, Oxfordshire, UNITED KINGDOM;
 Austen Pimm, Loughborough, UNITED KINGDOM;
 Philip Thorne, Loughborough, UNITED KINGDOM;
 Paul Willis, Loughborough, UNITED KINGDOM;

MOYA CAPFREY, LOUGHBOROUGH,
 UNITED KINGDOM
 TIMOTHY LUKER, LOUGHBOROUGH,
 UNITED KINGDOM

Assignment For Published Patent Application

AstraZeneca AB

Power of Attorney:

Donald Bird-25323

Domestic Priority data as claimed by applicant

This application is a CON of 10/149,549 06/12/2002
 which is a 371 of PCT/SE00/02505 12/12/2000

Foreign Applications

SWEDEN 9904651-8 12/17/1999
 UNITED KINGDOM 0015744.6 06/27/2000
 UNITED KINGDOM 0017942.4 07/22/2000

RECEIVED

NOV 24 2004

If Required, Foreign Filing License Granted: 08/10/2004

MORGAN, LEWIS & BOCKIUS LLP

56291-5103-01
DOCKETED
 By PSC Date 11/24/04

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/813,426**

Projected Publication Date: 03/03/2005

Non-Publication Request: No

Early Publication Request: No

Title

Adamantane derivatives

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).